The safety and immunogenicity of 5 acellular pertussis vaccines (ACVs) were compared in a multicenter, randomized, double-blind trial. A total of 481 healthy adults were given a single intramuscular booster dose of ACV or placebo. Three different dose levels were tested for 4 ACVs: full strength (the dose level proposed for infant immunization), one-third strength, and one-tenth strength. For 1 multicomponent vaccine, only the pertussis toxoid dose level varied. Minor injection site reactions were common and similar in frequency among vaccinated groups. Late-onset injection site reactions were seen in all ACV groups. Dose-related increases in mean antibody titers against vaccine antigens were seen after immunization with all ACVs. Antibody responses against antigens not known to be present in the vaccines were detected after immunization with 4/5 ACVs. Antibody levels fell significantly during the year after immunization. These data support evaluation of ACVs for broader use among adolescents and adults.
fants with whole-cell pertussis vaccines (WCVs) was the primary stimulus for the development of acellular pertussis vaccines (ACVs) [9] . A high level of reactogenicity also has been observed among adults given WCVs [10, 11] . Candidate ACVs contain 1 or more purified antigens, including pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbrial agglutinogens (FIM). Earlier studies using a single vaccine [12] [13] [14] [15] [16] [17] [18] demonstrated the safety and immunogencity of ACVs in limited numbers of adults. The goals of this expanded study were to compare simultaneously the immunogenicity and reactogenicity of varying doses of 5 different ACVs in healthy adults.
Materials and Methods
Vaccines. Five ACVs formulated to contain 1-4 purified components of B. pertussis (PT, FHA, PRN, or FIM) in varying quantities and produced by use of different manufacturing methods were compared: 1 monocomponent PT vaccine provided by North American Vaccine (Amvax-1; Beltsville, MD); 1 2-component vaccine containing PT and FHA provided by Massachusetts Public Health Biologics Laboratories (Mass-2; Boston); 2 3-component vaccines containing PT, FHA, and PRN provided by Chiron/Biocine (Biocine-3P; Emeryville, CA) and SmithKline Beecham Biologicals (SKB-3P; Rixensaart, Belgium); and 1 multicomponent vaccine containing PT, FHA, PRN, and FIM provided by Connaught Laboratories (CLL-4F; Willowdale, Ontario, Canada; table 1). A single lot of each vaccine was used for the trial.
Three dose levels of each vaccine were evaluated. In most cases, the high dose of vaccine was the dose level proposed for primary immunization of infants. For ACVs containing 1-3 components, the content of each antigen in the medium and low doses was onethird and one-tenth of that found in the high dose level, respectively. For the CLL-4F vaccine, only the PT content varied (5, 2.5, or 1 mg per dose); the concentrations of the other antigens remained constant. Subjects. Healthy subjects between the ages of 18 and 45 years who had no history of immunization against pertussis or confirmed infection caused by B. pertussis within the past 10 years were recruited to participate by use of protocols approved by institutional review boards at each participating institution. Subjects were recruited from institutions of higher education, medical center campuses, and the community. Potential subjects were excluded if they reported a history of a severe reaction temporally associated with receipt of a pertussis vaccine in childhood or history of childhood immunization with diphtheria-tetanus vaccine rather than diphtheria-tetanus toxoid-pertussis (DTP) vaccine, if the possibility of a prior adverse reaction to DTP vaccine could not be excluded.
Study design. The double-blind, randomized, placebo-controlled trial was conducted at 4 Vaccine and Treatment Evaluation Units (VTEUs) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The VTEUs (and secondary sites) included were Baylor College of Medicine (Houston, TX; also Texas A&M University, College Station), Vanderbilt University (Nashville, TN), Saint Louis University Medical Center (St. Louis), and Harbor-UCLA Medical Center (Torrance, CA). Eligible subjects were stratified by site of enrollment, then randomized to receive 1 of 3 dose levels of 1 of 5 vaccines or placebo (16 groups; approximately 30 subjects per dose group).
Clinical protocol. After informed consent was obtained, subjects were randomized to receive a single 0.5-mL dose of ACV or placebo in the deltoid muscle by use of a 1-inch 25-gauge needle (day 0). A daily log of oral temperature, systemic symptoms, and injection site findings was maintained during the first week. Redness and swelling at the injection site were measured by determining the length and width of the reaction. For weeks 2-4, a second diary was provided to record any local or systemic symptoms or signs. All subjects were examined by a member of the study team on days 2, 7, 14, and 28 after inoculation. Blood samples for antibody assays were collected from all subjects before, 1 month after, and 1 year after inoculation.
Laboratory methods. Serum aliquots were stored frozen (Ϫ20ЊC) and shipped on dry ice. Serum IgG antibody levels against PT, FHA, PRN, and FIM were assayed in all samples by ELISA by use of standard procedures at Vanderbilt University [19] . The lower limit of detection for all antigens was 1 ELISA unit (EU)/ mL. Values less than the lower limit were entered as 1 EU/mL. Chinese hamster ovary (CHO) cell neutralizing and agglutinating (AGG) antibody levels also were assayed in a randomly selected subset of samples (10%).
Statistical methods. A у4-fold increase in antibody levels between preimmunization and 1-month postimmunization samples was defined as seroresponse. Geometric mean titers or concentrations of antibody (GMCs) were calculated by group and compared by use of the paired t test or analysis of variance (ANOVA), as appropriate. Differences in proportions were compared by use of the x 2 test. Dose-response comparisons for frequencies of reactions and seroresponses were analyzed by use of the x 2 test for linear trend. Correlations between CHO and AGG assays with those determined by use of ELISA assays were assessed by use of Pearson correlation coefficients. Relationships of postimmunization titers to other subject-specific features were analyzed by linear regression of log titer, adjusted for preimmunization log titers.
Definition of vaccine reactions. Oral temperature у100.0ЊF (37.8ЊC) was considered to be a fever. Local symptoms (pain or tenderness at the injection site) and systemic symptoms (chills, headache, bodyache, decreased energy, or nausea) were graded on a scale of 0-3, where 0 is none, 1 (mild) is awareness of symptom but easily tolerated, 2 (moderate) is discomfort enough to interfere with usual activity, and 3 (severe) is incapacitating, unable to perform usual activities. Development of a new symptom or sign 13 days after immunization was considered to represent late onset, because typical injection site reactions after primary immunization with pertussis vaccines in children usually develop within the first 2 days [20] . Recurrent injection site symptoms or signs after at least for frequency of late-onset/biphasic reaction rates with increasing dose level. P ϭ .02 a 1-day interval free of symptoms or signs were considered to be biphasic.
Results
Subject enrollment. A total of 481 subjects (29-32/group) were enrolled into the trial. Of these, 480 (199%) and 453 (94%), respectively, returned for follow-up at 1 month and 1 year. No significant differences in sex, race, age, or country of origin were observed by vaccine group or vaccine dose level. The mean age for each of the 16 study groups ranged from 27 to 32 years (P not significant), and the overall female:male ratio was 1.6: 1 (data not shown).
Systemic reactions. There were no significant differences in the rates of systemic symptoms during the week after inoculation among subjects given the highest (or reference) dose levels of vaccine or placebo (data not shown). Two subjects developed fever (both !101ЊF) associated with injection site reactions on day 7 after immunization (1 given the medium dose level of Mass-2 and 1 given the high dose level of CLL-4F). Transient arthralgias developed in 6 subjects given various dose levels of 4 of the ACVs (Mass-2, Biocine-3P, and SKB-3P, 1 subject each; CLL-4F, 3 subjects). Transient hives developed in 2 subjects who were given SKB-3P vaccine, 1 of whom had a history of idiopathic urticaria. An allergic reaction to guinea pigs (wheezing and urticaria) occurred 1 day after immunization in a subject given Biocine-3P; this subject had a history of guinea pig allergy associated with upper respiratory symptoms only.
Injection site reactions. Injection site discomfort during the week after immunization was seen in the majority of subjects given vaccine and in most cases was mild (table 2) . Among subjects given the highest dose levels of vaccine, the frequencies of injection site symptoms and signs did not differ significantly by vaccine. Large local reactions (125 cm 2 ) were seen in subjects given all but the Amvax-1 vaccine but were infrequent and not clearly dose-related (data not shown).
Late-onset or biphasic injection site symptoms (pain or tenderness) or signs (erythema or induration) occurred in all groups given ACVs. The frequency of these reactions among groups given the highest dose levels of ACV increased with increasing numbers of antigens in the vaccine ( ; Coch-P ϭ .01 ran-Mantel-Haenszel [CMH] x 2 test for trend; table 2). Most late-onset/biphasic reactions started between 4 and 7 days after immunization and resolved by day 10, and most reactions were mild. Although the majority of subjects with late-onset or biphasic injection site reactions also reported injection site reactions within the first 3 days, 29% (16/56) experienced no antecedent symptoms or signs. The frequencies of injection site discomfort during the 2d-4th weeks after immunization, and of late-onset/biphasic reactions, were significantly related to dose level only for SKB-3P ( and .02, respectively; CMH P ! .01 x 2 test for trend). Prolonged pain and sensations of weakness in the injected arm were seen in 1 subject given the low dose level of Amvax-1 vaccine and 1 given the high dose level of CLL-4F. In the subject given Amvax-1, symptoms started on day 17 and had resolved by 1 month; injection site tenderness, axillary adenopathy, and dysesthesias of the hand also were noted. For the subject given CLL-4F, a large local reaction developed on day 6 that resolved by day 9; extremity and injection site pain and tenderness resolved by day 25.
Antibody responses. Preimmunization antibody titers were similar for all groups. Postimmunization titers did not differ significantly by site. Antibody titers 1 month after immunization and the percentage with a у4-fold rise in antibody level between pre-and 1-month postimmunization serum samples are shown in figure 1 . No significant increases in mean serum antibody levels against any vaccine antigen were seen in the placebo group. Statistically significant increases in PT antibody levels were observed 1 month after immunization in all vaccine groups ( for each comparison; paired t test; figure 1A ). P ! .0001 Dose-related increases in PT antibody levels were seen for each of the 5 vaccines (
; linear regression of titer on dose). P ! .005 PT antibody levels at 1 month were similar for the highest doses of each vaccine, with the exception of CLL-4F, which was significantly lower than the other groups ( ; one-way P ! .001 ANOVA). Postimmunization levels of CHO cell neutralizing antibody correlated well with postimmunization IgG PT antibody levels as measured by use of the ELISA (Pearson ; ). correlation ϭ 0.816 P ! .0001
The source of PT antigen also was a significant determinant of the magnitude of the serum antibody response when dose level was controlled for, as shown in figure 2 . The Biocine/ Chiron vaccine had the most immunogenic PT when similar dose levels were compared, followed by the PT contained in the Mass-2 vaccine. Levels of antibody elicited by PT contained in the Amvax-1, SKB-3P, and CLL-4F vaccines were similar.
FHA antibody levels (figure 1B) were significantly higher 1 month after immunization in all ACV dose groups, including Amvax-1, which was not formulated to contain FHA (P ! ; paired t test), and significant ( ; linear regression .0001 P ! .0001 of titer on dose) dose-response relationships for FHA antibody were noted for all but the CLL-4F vaccine, for which the dose of FHA was held constant. When the highest dose levels of the 4 vaccines formulated to contain FHA were compared, antibody levels at 1 month were highest in recipients of SKB-3P, followed by Biocine-3P, CLL-4F, and Mass-2 (overall P ! ; ANOVA). .001
Significant antibody responses against PRN were observed only in recipients of vaccines formulated to contain PRN: Biocine-3P, SKB-3P, and CLL-4F ( ; paired t-test; figure P ! .0001 1C). PRN antibody responses varied with dose levels for the 2 vaccines whose PRN content varied, Biocine-3P and SKB-3P ( ; linear regression of titer on dose). The high dose P ! .0003 levels of Biocine-3P and SKB-3P were shown to elicit similar levels of antibody; these were higher than those elicited by CLL-4F (overall ; ANOVA). P ! .001 Finally, for all dose levels of Mass-2, SKB-3P, and CLL-4F, postimmunization FIM levels differed significantly from preimmunization levels, although only CLL-4F vaccine was formulated to contain FIM ( figure 1D ). Small (!2-fold) but significant increases in mean FIM antibody levels also were seen in subjects given the medium and high dose levels of Biocine-3 and the high dose level of Amvax-1. When high dose levels of all vaccines were compared, antibody levels at 1 month were highest in recipients of CLL-4F, followed by Mass-2, Amvax-1, Biocine-3P, and SKB-3P (overall ; ANOVA). P ! .001 Postimmunization levels of AGG antibody correlated well with postimmunization FIM antibody levels (Pearson correlation ϭ 0.848;
). P ! .0001 Serum antibody levels 1 year after immunization were significantly lower than 1-month levels for all known vaccine antigens ( figure 3 ). For the high dose levels of each vaccine, the amount of antibody remaining at 1 year ranged between 21% and 41% of the level present 1 month after immunization ( for all comparisons; paired t tests). Levels of anti-P ! .001 bodies present at 1 year remained 2-to 30-fold higher than preimmunization levels ( ; paired t-tests). P ! .001 Relationship of local reactions to serum antibody responses. Preimmunization PT antibody levels were associated with increased risk of injection site swelling ( ; regression of P ϭ .03 area of swelling on preimmunization antibody level). Subjects who reported redness or swelling at any time after immunization had higher postimmunization antibody levels against FHA and PRN than subjects without redness or swelling ( for both; regression of injection site reaction area on P ϭ .01 postimmunization antibody level adjusted for preimmunization level). Postimmunization FHA and FIM antibody levels were significantly higher in the 56 subjects with a late-onset or biphasic reaction when compared with subjects without this type of reaction (GMC for vs. 158, ; GMC for FHA ϭ 257 P ϭ .005 vs. 102, ; unpaired t test for log titer). FIM ϭ 182 P ! .05
Discussion
All 5 ACVs were safe and immunogenic. Significant differences in the frequencies of adverse reactions were not detected, although this could be due to the small sample size. Doserelated increases in serum antibody levels against known vaccine antigens were seen in all ACV groups. In general, serum antibody levels 1 month after a single booster dose were considerably higher in adults than those reported after primary or booster immunization of infants and young children with ACV [21, 22] . ELISA antibody levels among adults correlated closely with functional antibody levels, as noted previously for children [20] . Substantial declines in serum antibody levels were observed during the year after booster immunization, but levels remained elevated over preimmunization levels.
Biphasic or late-onset injection site reactions were seen after immunization with all 5 ACVs and were similar to those previously reported by others [12, 13, 15, 17] . Our data support the hypothesis that vigorous serum antibody responses to several pertussis antigens are associated with an increased risk of developing late-onset reactions, as has been observed after immunization with diphtheria toxoid [23] . Although monocomponent vaccines containing each of the individual components were not compared in this trial, late-onset biphasic reactions were associated with higher postimmunization levels of antibody to FHA and FIM. These late-onset/biphasic reactions, as well as the typical early-onset reactions, were generally mild and well tolerated. The reactogenicities of these ACVs compare favorably with that observed after immunization of adults with other licensed vaccines, including adult-formulation tetanus/ diphtheria toxoid [18] . The sample size of 30 subjects per group can detect clinical responses if they occur in at least 10% of the population from which the subjects are drawn, with at most a 5% error [24] . Larger studies will be necessary to explore the relationship between booster immunization of adults with ACV and the occurrence of rarer events, including arthralgias and allergic reactions.
Unexpected antibody responses to antigens not known to be present were noted for 4 of the ACVs. One possible explanation for these responses is the presence of small quantities of antigen(s) not previously known to be present in the vaccines. Significant dose-response relationships were observed in most instances, and the magnitude of the responses was consistent with the responses observed to known constituents. Unexpected antibody responses also have been observed among children given diphtheria-tetanus-acellular pertussis vaccine as a 4th dose after they had received 3 primary doses of WCV in combination with diphtheria and tetanus toxoids [22] and in children given booster doses of Takeda vaccine [25] . The significance of these responses with respect to protection is unknown.
Immunization with several ACVs during infancy confers significant protection against pertussis [26] ; however, the relative contributions of various antibodies directed against acellular components of B. pertussis have not been definitively established. Antibodies directed against candidate immunogens described herein can confer protection against experimental pertussis in animal models, and several (particularly antibodies against PT, PRN, and FIM) have been correlated with protection against human disease [3, 25, [27] [28] [29] [30] [31] . Cellular immune responses also appear to be involved in vaccine-induced immunity [32, 33] . An ongoing NIAID-supported prospective evaluation of the impact of pertussis in adolescents and adults and the efficacy of an ACV against pertussis in these age groups will help to define more clearly the correlates of immunity against B. pertussis and the need for booster immunization after childhood. The favorable reaction profile and high immunogenicity of ACV among adults suggest that these vaccines may serve as attractive candidates for use in adults, ultimately leading to improved control of pertussis. 
